HESTERBIO Hester Bios Q3 FY26 results (Oct–Dec 2025) and concall
Hester Biosciences reported a strong Q3 FY26 with stand-alone revenue growth of 12% and a significant 140% increase in PAT, primarily driven by the robust performance of its Poultry Healthcare division. The company also achieved a key regulatory milestone for its H9N2 Avian Influenza vaccine. However, the Animal Healthcare division faced headwinds with a 38% decline in Q3 due to delays in government immunization programs and seasonal factors, though management expects improved momentum in Q4.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 11.1%, net profit up 175.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 74 | 63 | 77 | 63 | 65 −12% | 70 +11% |
| EBITDA | 15 | 9 | 14 | 12 | 12 −20% | 17 +89% |
| Net profit | 9 | 4 | 10 | 8 | 7 −22% | 11 +175% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
